TMCI TREACE MEDICAL CONCEPTS, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1630627 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-7.1%
TTM net income YoY-11.3%
TTM EPS YoY-6.2%
Revenue 3-yr CAGR5.2%
Net income 3-yr CAGR—
Margins
Gross margin79.6%
Operating margin-24.4%
Net margin-27.4%
FCF margin-9.1%
EBITDA margin-21.1%
Returns
ROE-74.0%
ROA-29.7%
ROIC (approx.)-31.2%
Asset turnover1.08x
Leverage & solvency
Liabilities / assets65.6%
Debt / equity0.97x
Current ratio2.58x
Interest coverage-8.17x
Cash quality & payout
Operating cash flow / net income0.16x
Accruals ratio-25.0%
Payout ratio—
Capex / revenue4.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $212.69M | $209.36M |
| Cost of revenue | $42.94M | $41.09M |
| Gross profit | $169.75M | $168.26M |
| R&D expense | $20.28M | $20.59M |
| SG&A expense | $62.74M | $55.72M |
| Operating income | -$54.15M | -$55.69M |
| Interest expense | $5.32M | $5.26M |
| Income tax | $0 | $0 |
| Net income | -$59.00M | -$55.74M |
| EBITDA | -$43.53M | -$47.27M |
| EPS (basic) | -0.93 | -0.90 |
| EPS (diluted) | -0.93 | -0.90 |
| Weighted avg. shares (diluted) | 63.27M | 62.11M |
| Balance sheet | ||
| Cash & equivalents | $10.71M | $11.35M |
| Short-term investments | $37.66M | $64.33M |
| Receivables | $42.16M | $40.80M |
| Inventory | $36.03M | $39.26M |
| Current assets | $132.05M | $161.40M |
| PP&E, net | $29.75M | $25.95M |
| Goodwill | $12.81M | $12.81M |
| Intangibles | $7.12M | $8.07M |
| Total assets | $190.58M | $217.09M |
| Current liabilities | $30.64M | $34.92M |
| Short-term debt | $1.75M | $0 |
| Long-term debt | $55.58M | $53.31M |
| Total debt | $57.33M | $53.31M |
| Total liabilities | $103.25M | $104.20M |
| Shareholders' equity | $87.33M | $112.89M |
| Net debt | $46.62M | $41.96M |
| Cash flow statement | ||
| Operating cash flow | -$15.97M | -$37.17M |
| Capital expenditure | $13.52M | $11.59M |
| Free cash flow | -$29.49M | -$48.76M |
| Investing cash flow | $13.25M | $35.38M |
| Financing cash flow | $2.08M | $160,000 |
| Depreciation & amortization | $10.62M | $8.42M |
| Stock-based compensation | $33.82M | $30.60M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.